NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

巨細胞病毒(CMV)檢驗(體外診斷)-全球市場分析及預測模式(COVID-19對市場造成的影響)

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)

出版商 GlobalData 商品編碼 979515
出版日期 內容資訊 英文
訂單完成後即時交付
價格
巨細胞病毒(CMV)檢驗(體外診斷)-全球市場分析及預測模式(COVID-19對市場造成的影響) Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)
出版日期: 2020年12月15日內容資訊: 英文
簡介

本報告詳細探討2020年後COVID-19對全球巨細胞病毒測試市場的影響。巨細胞病毒(CMV)是引起全球範圍內先天性感染的廣泛分佈的病原體。CMV高危人群包括免疫力低下的患者(艾滋病患者或器官移植受者),早產兒和新生兒。

CMV是發達國家中最常見的先天性病毒感染,可引起兒童神經系統疾病以及感音神經性耳聾。先天性鉅細胞病毒感染發生在原發性和繼發性巨細胞病毒感染的婦女所生的孩子中,這意味著受孕前的免疫力無法抵抗病毒的傳播。

儘管傳播的風險較低,但研究表明,即使在工業化國家中,大多數先天性巨細胞病毒感染也歸因於繼發性(或非原發性)母體感染,這很可能是因為血清反應陽性的婦女發生了更多的妊娠。本報告涵蓋孕婦和免疫受損患者的CMV測試。

本報告提供巨細胞病毒(CMV)檢驗市場相關調查,提供市場概要,以及2015∼2030年的市場預測,各市場區隔,各國的趨勢等資訊。

  • 主要的產業趨勢洞察
  • 2015年∼2030年各分類市場預測
  • 手術數量,台數,平均銷售價格,各分類市場價值相關詳細資料

全球地區,各國趨勢

  • 各國分析
  • SWOT分析
  • 競爭趨勢

健康護理系統概要

  • 醫療保健制度的各國概要
  • 各國給付方針
  • 國家固有的醫療技術相關法規趨勢

網羅的企業:DiaSorin Spa,F. Hoffman-LaRoche Ltd,Qiagen NV,Quidel Corp,bioMerieux SA,Bio-Rad Labs Inc.,其他

觀察對象國家:美國,英國,德國,法國,義大利,西班牙,巴西,中國,印度,俄羅斯,日本,澳洲,加拿大,墨西哥,韓國,丹麥,愛爾蘭,荷蘭,紐西蘭,南非,瑞典,瑞士,奧地利,比利時,芬蘭,以色列,挪威,波蘭葡萄牙,台灣,捷克,希臘,匈牙利,土耳其,埃及,沙烏地阿拉伯,阿拉伯聯合大公國,阿根廷,智利

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME625MM

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Cytomegalovirus Test market for the year 2020 and beyond. Cytomegalovirus (CMV) is a widely distributed pathogen that causes congenital infection worldwide. Groups that are at high risk for CMV include immunocompromised patients (AIDS patients or organ transplant recipients), premature infants, and newborns.

CMV represents the most common congenital, viral infection in the developed world and can cause neurological diseases as well as sensorineural deafness in children. Congenital CMV infections occur in children born to women with both primary and secondary CMV infections, meaning that pre-conceptional immunity does not protect against transmission of the virus during pregnancy.

Despite a lower risk of transmission, studies suggest that even in industrialized countries, the majority of congenital CMV infections are due to secondary (or non-primary) maternal infection, likely because a greater number of pregnancies occur in seropositive women. This model covers CMV test for pregnant women cases as well as Immuno compromised patients.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Cytomegalovirus Tests and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Cytomegalovirus Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Cytomegalovirus Tests market.
  • Competitive dynamics insights and trends provided for Cytomegalovirus Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: DiaSorin Spa, F. Hoffman-La Roche Ltd, Qiagen NV, Quidel Corp, bioMerieux SA, Bio-Rad Labs Inc. and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Cytomegalovirus (CMV) Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Cytomegalovirus Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Cytomegalovirus Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cytomegalovirus Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Cytomegalovirus Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.